Oracle Recognized as a Leader in Everest Group PEAK Matrix® for Life Sciences Clinical Trial Management System (CTMS) Assessment 2024
Werte in diesem Artikel
Highlights ease of deployment, value, and extensibility of comprehensive Oracle platform
ORLANDO, Fla. , Feb. 3, 2025 /PRNewswire/ -- SCOPE 2025 – Oracle Life Sciences has been named a 'Leader' in the Everest Group Life Sciences Clinical Trial Management System (CTMS) Products PEAK Matrix® Assessment 2024. This designation underscores Oracle's ongoing commitment to transforming clinical trial management through innovative and cost-effective solutions designed to support healthcare systems and life sciences organizations worldwide.
As the life sciences industry evolves, driven by increasing trial complexities, regulatory demands, and the need for real-time insights, Oracle continues to redefine the industry standard for CTMS platforms. Oracle's Siebel CTMS platform enables integration with Electronic Health Records (EHR) for seamless data flow between investigators, Contract Research Organizations (CROs), and sponsors, integration with Electronic Data Capture (EDC), and other critical systems, and adherence to diverse regulatory standards.
"Being designated as a 'Leader' by Everest Group in its assessment of our CTMS validates Oracle's mission to deliver cutting-edge technology that accelerates innovation and helps improve outcomes in life sciences," said Seema Verma, executive vice president and general manager, Oracle Health and Life Sciences. "We are harnessing the full power of Oracle's expertise in data and AI to deliver platforms like CTMS, purpose-built to address the unique challenges of pharma and healthcare systems. Our solution is compliant, secure, cost-effective, and globally adaptable, empowering organizations to drive innovation and efficiency in clinical research and care delivery."
The evaluation highlights Oracle's strengths in providing a comprehensive solution to critical trial management and its abilities to accommodate diverse regulatory requirements globally. The report further highlights Oracle's competitive pricing and seamless integration with critical clinical systems, including EDC, Clinical Data Management Systems (CDMS), electronic trial master file (eTMF), payment, analytics, and regulatory systems.
"The CTMS market is rapidly evolving in response to growing trial complexity, the need for real-time collaboration, and diverse data sources' integration," said Nisarg Shah, practice director, Everest Group. "Providers are now delivering comprehensive trial data management solutions that offer enhanced features to elevate the quality of information provided."
"Oracle's Siebel CTMS platform offers a comprehensive, one-stop-shop solution for clinical trial management, providing flexibility for customization to meet specific organizational needs. Clients value the platform's seamless integration with various critical clinical systems and analytics solutions. Oracle's extensive global footprint, which helps deliver consistent operations across regions, combined with its expansive capabilities and competitive pricing have positioned Oracle as a Leader in the Life Sciences Clinical Trial Management System (CTMS) Products PEAK Matrix® Assessment 2024."
The Everest Group PEAK Matrix® is a proprietary framework for assessing the relative market success and overall capability of service providers based on performance, experiences, ability, and knowledge. Each service provider is comparatively assessed on two dimensions: market success and delivery capabilities. Market success is measured by revenue, number of clients, and year-over-year growth. Delivery capability is measured by scale of operations, scope, technology and innovation, delivery footprint, and buyer satisfaction. The resulting matrix categorizes service providers as Leaders, Major Contenders, and Aspirants.
To read the full Everest Group PEAK Matrix® report, visit: https://www.everestgrp.com/peak-matrix/healthcare-and-life-sciences/life-sciences-clinical-trial-management-system-ctms-products.html
To read about Oracle and the Everest Group PEAK Matrix® for Electronic Data Capture, visit: https://www.oracle.com/news/announcement/oracle-life-sciences-positioned-as-a-leader-in-the-everest-group-peak-matrix-for-electronic-data-capture-2024-10-24/
About Oracle Life Sciences
Oracle Life Sciences is a leader in cloud technology, pharmaceutical research, and consulting, trusted globally by professionals in both large and emerging companies engaged in clinical research and pharmacovigilance, throughout the therapeutic development lifecycle, including pre- and post-drug launch activities. With more than 20 years of experience, Oracle Life Sciences is committed to supporting clinical development and leveraging real-world evidence to deliver innovation and accelerate advancements – empowering the life sciences industry to improve patient outcomes. Learn more at oracle.com/lifesciences
About Oracle
Oracle offers integrated suites of applications plus secure, autonomous infrastructure in the Oracle Cloud. For more information about Oracle (NYSE: ORCL), please visit us at www.oracle.com.
Disclaimer
Licensed extracts taken from Everest Group's PEAK Matrix® Reports, may be used by licensed third parties for use in their own marketing and promotional activities and collateral. Selected extracts from Everest Group's PEAK Matrix® reports do not necessarily provide the full context of our research and analysis. All research and analysis conducted by Everest Group's analysts and included in Everest Group's PEAK Matrix® reports is independent and no organization has paid a fee to be featured or to influence their ranking. To access the complete research and to learn more about our methodology, please visit Everest Group PEAK Matrix® Reports.
About Everest Group
Everest Group is a leading global research firm helping business leaders make confident decisions. Everest Group's PEAK Matrix® assessments provide the analysis and insights enterprises need to make critical selection decisions about global services providers, locations, and products and solutions within various market segments. Likewise, providers of these services, products, and solutions, look to the PEAK Matrix® to gauge and calibrate their offerings against others in the industry or market. Find further details and in-depth content at www.everestgrp.com.
Trademarks
Oracle, Java, MySQL and NetSuite are registered trademarks of Oracle Corporation. NetSuite was the first cloud company—ushering in the new era of cloud computing.
View original content to download multimedia:https://www.prnewswire.com/news-releases/oracle-recognized-as-a-leader-in-everest-group-peak-matrix-for-life-sciences-clinical-trial-management-system-ctms-assessment-2024-302365733.html
SOURCE Oracle
Ausgewählte Hebelprodukte auf Oracle
Mit Knock-outs können spekulative Anleger überproportional an Kursbewegungen partizipieren. Wählen Sie einfach den gewünschten Hebel und wir zeigen Ihnen passende Open-End Produkte auf Oracle
Der Hebel muss zwischen 2 und 20 liegen
Name | Hebel | KO | Emittent |
---|
Name | Hebel | KO | Emittent |
---|
Nachrichten zu Oracle Corp.
Analysen zu Oracle Corp.
Datum | Rating | Analyst | |
---|---|---|---|
27.01.2025 | Oracle Buy | Jefferies & Company Inc. | |
03.01.2025 | Oracle Sector Perform | RBC Capital Markets | |
10.12.2024 | Oracle Hold | Joh. Berenberg, Gossler & Co. KG (Berenberg Bank) | |
10.12.2024 | Oracle Sector Perform | RBC Capital Markets | |
10.12.2024 | Oracle Neutral | JP Morgan Chase & Co. |
Datum | Rating | Analyst | |
---|---|---|---|
27.01.2025 | Oracle Buy | Jefferies & Company Inc. | |
10.12.2024 | Oracle Buy | UBS AG | |
10.12.2024 | Oracle Buy | Jefferies & Company Inc. | |
05.12.2024 | Oracle Buy | Jefferies & Company Inc. | |
30.09.2024 | Oracle Kaufen | DZ BANK |
Datum | Rating | Analyst | |
---|---|---|---|
03.01.2025 | Oracle Sector Perform | RBC Capital Markets | |
10.12.2024 | Oracle Hold | Joh. Berenberg, Gossler & Co. KG (Berenberg Bank) | |
10.12.2024 | Oracle Sector Perform | RBC Capital Markets | |
10.12.2024 | Oracle Neutral | JP Morgan Chase & Co. | |
23.10.2024 | Oracle Sector Perform | RBC Capital Markets |
Datum | Rating | Analyst | |
---|---|---|---|
13.12.2022 | Oracle Sell | Goldman Sachs Group Inc. | |
21.10.2022 | Oracle Sell | Goldman Sachs Group Inc. | |
19.03.2019 | Oracle Verkaufen | DZ BANK | |
17.09.2015 | Oracle Sell | Joh. Berenberg, Gossler & Co. KG (Berenberg Bank) | |
08.01.2015 | Oracle Sell | Joh. Berenberg, Gossler & Co. KG (Berenberg Bank) |
Um die Übersicht zu verbessern, haben Sie die Möglichkeit, die Analysen für Oracle Corp. nach folgenden Kriterien zu filtern.
Alle: Alle Empfehlungen